查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571821

基於人工智慧的臨床試驗解決方案供應商市場規模、佔有率和趨勢分析報告：按治療應用、按臨床試驗階段、按最終用途、按地區、按細分市場、預測，2024-2030 年

AI-based Clinical Trials Solution Provider Market Size, Share & Trends Analysis Report By Therapeutic Application, By Clinical Trial Phase, By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 118 Pages | 商品交期: 2-10個工作天內

價格

基於人工智慧的臨床試驗解決方案供應商市場成長和趨勢：

根據 Grand View Research, Inc. 的最新報告，到 2030 年，基於人工智慧的臨床試驗解決方案供應商的全球市場規模預計將達到 78 億美元，預測期內複合年成長率為 22.1%。

人工智慧是一種多功能工具，擴大用於提高藥物研究的運作效率並加速藥物發現過程。它也被大量使用以最大限度地降低藥物開發過程中的成本。各個學術界和製藥公司正在積極採用基於人工智慧的平台和技術。例如，2020 年 1 月，拜耳與一家英國人工智慧主導的藥物發現公司建立了夥伴關係，利用其人工智慧藥物發現平台進行早期研究計劃。此外，公共和私人促進研發的措施以及人工智慧在藥物研究領域提供的多樣化應用正在推動成長。

從臨床試驗階段來看，由於藥物發現數量不斷增加以及二期臨床試驗數量眾多，二期臨床試驗將在 2023 年以 45.5% 的佔有率佔據市場主導地位。此外，在此階段擴大採用基於人工智慧的工具來收集資料並透過臨床試驗即時分析整體預期結果，這也有助於該細分市場的成長。此外，由於在此階段可以對基於人工智慧的工具進行改進、決策和措施檢驗，因此該細分市場擁有更高的收益佔有率。

基於治療應用，腫瘤學在 2023 年基於人工智慧的臨床試驗解決方案供應商市場中佔據最高收益佔有率。全球癌症盛行率的不斷上升以及腫瘤學領域藥物研究數量的增加正在促進人工智慧技術的採用。此外，越來越多的參與者正在開發先進的基於腫瘤學的人工智慧工具，並將其用於藥物研究，從而推動了這一領域的成長。

2023年，根據最終用途，製藥公司在市場上佔據最高的收益佔有率。大型製藥企業擴大採用基於人工智慧的技術來識別新藥靶點、開發新藥和新藥測試的整個流程、診斷和生物標記的更好開發是該細分市場成長的主要因素之一。此外，這些大型製藥企業正在與人工智慧供應商合作，在整個研發和藥物發現過程中利用人工智慧技術，這推動了它們的成長。

北美地區主導市場，2023 年收益佔有率為 43.4%。這一優勢得益於該地區新興企業數量的不斷增加。例如，Bullfrog AI 是一家總部位於美國的新興企業，它開發了 bfLEAP，這是一個支援精準醫療的專有人工智慧平台。此外，人們對基於人工智慧的技術的認知不斷增強，並採用這些技術來提高藥物研究成果，正在推動該地區的市場成長。此外，政府支持措施的增加和領先公司的戰略舉措正在推動該地區對基於人工智慧的臨床試驗解決方案的需求。

由於 COVID-19 的爆發，基於人工智慧的技術的採用激增。擴大採用技術先進的解決方案來進行藥物開發和招募患者的資料分析，這有助於人工智慧解決方案的快速採用。此外，許多藥物開發過程在大流行期間被擱置。因此，市場上的許多主要企業已將重點轉向利用基於人工智慧的解決方案，從而促進分散的臨床臨床實驗。此外，透過這些解決方案對大量患者資料進行有效分析也支持了市場成長。

基於人工智慧的臨床試驗解決方案供應商市場報告亮點

  • II 期臨床試驗部分在 2023 年佔據市場主導地位。
  • 由於癌症盛行率上升以及腫瘤學藥物研究的增加，腫瘤學領域將在 2023 年佔據市場主導地位。
  • 由於大型製藥企業擴大採用人工智慧技術進行藥物開發，製藥公司部門在市場上佔據了最高的收益佔有率。
  • 北美地區佔據主導地位，2023 年收益佔有率為 43.4%。這是由於多種因素造成的，包括該地區臨床試驗數量的增加、人工智慧平台和工具的更多採用、基於人工智慧的藥物開發新興企業公司和公司數量的增加以及這是由於人們對基於人工智慧的工具和技術的認知所造成的。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 基於人工智慧的臨床試驗解決方案供應商市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19 的影響
  • 案例研究

第4章 基於人工智慧的臨床試驗解決方案供應商市場：治療應用的估算和趨勢分析

  • 細分儀表板
  • 2023 年和 2030 年治療應用趨勢和市場佔有率分析
  • 按治療應用分類的基於人工智慧的臨床試驗解決方案供應商的全球市場前景
  • 腫瘤學
  • CVD
  • 神經系統疾病或病症
  • 代謝性疾病
  • 感染疾病
  • 其他

第5章 人工智慧的臨床試驗解決方案供應商市場：臨床試驗階段估算及趨勢分析

  • 細分儀表板
  • 2023年及2030年臨床試驗階段趨勢及市場佔有率分析
  • 基於人工智慧的臨床試驗解決方案供應商市場的全球展望（按臨床試驗階段）
  • 第一階段
  • 第二階段
  • 第三階段

第6章 基於人工智慧的臨床試驗解決方案供應商市場：最終用途估計和趨勢分析

  • 細分儀表板
  • 2023 年和 2030 年最終用途趨勢和市場佔有率分析
  • 基於人工智慧的臨床試驗解決方案供應商的最終用途市場前景
  • 製藥公司
  • 學術的
  • 其他

第7章基於人工智慧的臨床試驗解決方案供應商市場：區域估計和趨勢分析，按治療應用，按臨床試驗階段，按最終用途

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場簡介
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 2023年主要企業市場佔有率/地位分析
  • 公司簡介
    • Unlearn.ai, Inc.
    • Saama
    • Antidote Technologies, Inc.
    • Phesi
    • Deep6.ai
    • Innoplexus
    • Mendel Health Inc.
    • Intelligencia AI
    • Median Technologies
    • SymphonyAI
    • BioAge Labs, Inc.
    • AiCure
    • Consilx
    • DeepLens.AI
    • HaloHealth
    • PHARMASEAL
    • Ardigen
    • Trials.ai
    • Koneksa Health
    • Euretos
    • BioSymetrics, Inc.
    • Verily（Google LLC）
    • Aitia
    • IBM
    • Exscientia
Product Code: GVR-4-68039-456-6

AI-based Clinical Trials Solution Provider Market Growth & Trends:

The global AI-based clinical trials solution provider market size is expected to reach USD 7.8 billion by 2030, registering a CAGR of 22.1% during the forecast period, according to a new report by Grand View Research, Inc.. AI is a versatile tool and is being increasingly utilized to improve the operational efficacy of drug studies and accelerate the drug discovery process. Also, it is highly adopted to minimize the cost of the drug development process. Various academia and pharmaceutical companies are actively adopting AI-based platforms and technologies. For instance, in January 2020, Bayer entered into a partnership with an AI-driven drug discovery company based in the UK to work on early research projects using the AI drug discovery platform. Furthermore, the initiatives by the public and private sectors to boost the R&D coupled with the diverse applications provided by AI in the field of drug studies are impelling the growth.

Based on the phase of the clinical trial, Phase II dominated the market with a share of 45.5% in 2023 owing to the rising number of drug discoveries and a large number of studies active in the second phase. Moreover, the increasing adoption of AI-based tools for the collection of data and the analysis of immediate outcomes of the overall desired outcome through the clinical trials in this phase is contributing to the segment growth. Furthermore, the segment holds a higher revenue share as the improvement, determination, and validation of measures with respect to the AI-based tool can be carried out in this phase.

In 2023, based on therapeutic applications, oncology accounted for the highest revenue share in the AI-based clinical trials solution provider market. The increasing prevalence of cancer across the globe and the rising number of drug studies in the field of oncology is contributing to the adoption of AI enables technologies. Also, an increasing number of players are developing and adopting advanced oncology-based AI tools for drug studies, thereby propelling the segment growth.

In 2023, pharmaceutical companies accounted for the highest revenue share in the market, based on end-use. The rising adoption of AI-based technologies for the better development of diagnostic and biomarkers, to identify the new drug target and the overall process of drug development and drug trials by major pharmaceutical players is one of the major factors contributing to the segment growth. Moreover, these major pharmaceutical players are collaborating with the AI vendor for leveraging the AI technology for R&D and the overall drug discovery process, thereby, impelling the growth.

North America dominated the market and accounted for a revenue share of 43.4% in 2023. This dominance is attributed to the rising number of start-ups in the region. For instance, Bullfrog AI is a U.S.-based startup that develops bfLEAP, a proprietary AI platform to enable precision medicine. Also, the growing awareness of AI-based technologies and their adoption to enhance the drug studies' outcomes is impelling the market growth in the region. Furthermore, the supportive government initiatives and increasing strategic initiatives by major players are driving the demand for AI-based clinical trial solutions in the region.

The AI-based technologies witnessed a surge in their adoption due to the outbreak of COVID-19. This increasing adoption of technologically advanced solutions for drug development and for the analyses of the recruited patient's data contributed to the upsurge in the adoption of AI-enabled solutions. Moreover, many drug development processes were on hold during the pandemic. Therefore, many key companies in the market shifted their focus on the utilization of AI-based solutions, thereby boosting decentralized drug trials. Furthermore, the effective analysis of a large amount of patient data through these solutions supported the market growth.

AI-based Clinical Trials Solution Provider Market Report Highlights:

  • The phase-II trials segment dominated the market in 2023, owing to the increasing number of active drug studies in this phase
  • The oncology segment dominated the market in 2023, owing to the rising prevalence of cancer and the growing number of drug studies in the oncology field
  • The pharmaceutical companies segment accounted for the highest revenue share in the market owing to the increasing adoption of artificial intelligence technologies for drug development by major pharmaceutical players
  • North America dominated the market and accounted for a revenue share of 43.4% in 2023, owing to various factors including the increasing number of clinical trials in the region, growing adoption of artificial intelligence platforms and tools, rising number of start-ups and companies based on artificial intelligence in drug development and growing awareness regarding AI-based tools and technologies.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Therapeutic applications
    • 1.1.2. Clinical trial phase
    • 1.1.3. End use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Therapeutic applications outlook
    • 2.2.2. Clinical trial phase outlook
    • 2.2.3. End use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. AI-Based Clinical Trials Solution Providers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape
    • 3.3.3. COVID-19 Impact
  • 3.4. Case Studies

Chapter 4. AI-Based Clinical Trials Solution Providers Market: Therapeutic Applications Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Therapeutic Applications Movement & Market Share Analysis, 2023 & 2030
  • 4.3. Global AI-Based Clinical Trials Solution Providers Market by Therapeutic Applications Outlook
  • 4.4. Oncology
    • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5. CVD
    • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million) CVD
  • 4.6. Neurological Diseases or Conditions
    • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.7. Metabolic Diseases
    • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.8. Infectious Diseases
    • 4.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. AI-Based Clinical Trials Solution Providers Market: Clinical Trial Phase Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Clinical Trial Phase Movement & Market Share Analysis, 2023 & 2030
  • 5.3. Global AI-Based Clinical Trials Solution Providers Market by Clinical Trial Phase Outlook
  • 5.4. Phase-I
    • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5. Phase-II
    • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.6. Phase-III
    • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. AI-Based Clinical Trials Solution Providers Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. End Use Movement & Market Share Analysis, 2023 & 2030
  • 6.3. Global AI-Based Clinical Trials Solution Providers Market by End Use Outlook
  • 6.4. Pharmaceutical Companies
    • 6.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5. Academia
    • 6.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. AI-Based Clinical Trials Solution Providers Market: Regional Estimates & Trend Analysis, By Therapeutic Applications, By Clinical Trial Phase, By End Use

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Key company market share/position analysis, 2023
  • 8.4. Company Profiles
    • 8.4.1. Unlearn.ai, Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Technology Type benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Saama
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Technology Type benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Antidote Technologies, Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Technology Type benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Phesi
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Technology Type benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Deep6.ai
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Technology Type benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Innoplexus
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Technology Type benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Mendel Health Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Technology Type benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Intelligencia AI
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Technology Type benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Median Technologies
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Technology Type benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. SymphonyAI
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Technology Type benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. BioAge Labs, Inc.
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Technology Type benchmarking
      • 8.4.11.4. Strategic initiatives
    • 8.4.12. AiCure
      • 8.4.12.1. Company overview
      • 8.4.12.2. Financial performance
      • 8.4.12.3. Technology Type benchmarking
      • 8.4.12.4. Strategic initiatives
    • 8.4.13. Consilx
      • 8.4.13.1. Company overview
      • 8.4.13.2. Financial performance
      • 8.4.13.3. Technology Type benchmarking
      • 8.4.13.4. Strategic initiatives
    • 8.4.14. DeepLens.AI
      • 8.4.14.1. Company overview
      • 8.4.14.2. Financial performance
      • 8.4.14.3. Technology Type benchmarking
      • 8.4.14.4. Strategic initiatives
    • 8.4.15. HaloHealth
      • 8.4.15.1. Company overview
      • 8.4.15.2. Financial performance
      • 8.4.15.3. Technology Type benchmarking
      • 8.4.15.4. Strategic initiatives
    • 8.4.16. PHARMASEAL
      • 8.4.16.1. Company overview
      • 8.4.16.2. Financial performance
      • 8.4.16.3. Technology Type benchmarking
      • 8.4.16.4. Strategic initiatives
    • 8.4.17. Ardigen
      • 8.4.17.1. Company overview
      • 8.4.17.2. Financial performance
      • 8.4.17.3. Technology Type benchmarking
      • 8.4.17.4. Strategic initiatives
    • 8.4.18. Trials.ai
      • 8.4.18.1. Company overview
      • 8.4.18.2. Financial performance
      • 8.4.18.3. Technology Type benchmarking
      • 8.4.18.4. Strategic initiatives
    • 8.4.19. Koneksa Health
      • 8.4.19.1. Company overview
      • 8.4.19.2. Financial performance
      • 8.4.19.3. Technology Type benchmarking
      • 8.4.19.4. Strategic initiatives
    • 8.4.20. Euretos
      • 8.4.20.1. Company overview
      • 8.4.20.2. Financial performance
      • 8.4.20.3. Technology Type benchmarking
      • 8.4.20.4. Strategic initiatives
    • 8.4.21. BioSymetrics, Inc.
      • 8.4.21.1. Company overview
      • 8.4.21.2. Financial performance
      • 8.4.21.3. Technology Type benchmarking
      • 8.4.21.4. Strategic initiatives
    • 8.4.22. Verily (Google LLC)
      • 8.4.22.1. Company overview
      • 8.4.22.2. Financial performance
      • 8.4.22.3. Technology Type benchmarking
      • 8.4.22.4. Strategic initiatives
    • 8.4.23. Aitia
      • 8.4.23.1. Company overview
      • 8.4.23.2. Financial performance
      • 8.4.23.3. Technology Type benchmarking
      • 8.4.23.4. Strategic initiatives
    • 8.4.24. IBM
      • 8.4.24.1. Company overview
      • 8.4.24.2. Financial performance
      • 8.4.24.3. Technology Type benchmarking
      • 8.4.24.4. Strategic initiatives
    • 8.4.25. Exscientia
      • 8.4.25.1. Company overview
      • 8.4.25.2. Financial performance
      • 8.4.25.3. Technology Type benchmarking
      • 8.4.25.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America AI-based clinical trials solution providers market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 4 North America AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 5 North America AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 6 U.S. AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 7 U.S. AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 8 U.S. AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 10 Canada AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 11 Canada AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Europe AI-based clinical trials solution providers market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 14 Europe AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 15 Europe AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 16 Germany AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 17 Germany AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 18 Germany AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 19 UK AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 20 UK AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 21 UK AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 22 France AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 23 France AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 24 France AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 25 Italy AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 26 Italy AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 27 Italy AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Spain AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 29 Spain AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 30 Spain AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 31 Denmark AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 32 Denmark AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 33 Denmark AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Sweden AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 35 Sweden AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 36 Sweden AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Norway AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 38 Norway AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 39 Norway AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific AI-based clinical trials solution providers market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 44 China AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 45 China AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 46 China AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Japan AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 48 Japan AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 49 Japan AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 50 India AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 51 India AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 52 India AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 53 South Korea AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 54 South Korea AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 55 South Korea AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Australia AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 57 Australia AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 58 Australia AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Thailand AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 60 Thailand AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 61 Thailand AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Latin America AI-based clinical trials solution providers market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 64 Latin America AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 65 Latin America AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 66 Brazil AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 67 Brazil AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 68 Brazil AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Argentina AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 70 Argentina AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 71 Argentina AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 72 Mexico AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 73 Mexico AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 74 Mexico AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 75 MEA AI-based clinical trials solution providers market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 77 MEA AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 78 MEA AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 79 South Africa AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 80 South Africa AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 81 South Africa AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 85 UAE AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 86 UAE AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 87 UAE AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 89 Kuwait AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 90 Kuwait AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 AI-Based Clinical Trials Solution Providers market: market outlook
  • Fig. 9 AI-Based Clinical Trials Solution Providers competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 AI-Based Clinical Trials Solution Providers market driver impact
  • Fig. 15 AI-Based Clinical Trials Solution Providers market restraint impact
  • Fig. 16 AI-Based Clinical Trials Solution Providers market strategic initiatives analysis
  • Fig. 17 AI-Based Clinical Trials Solution Providers market: Therapeutic applications movement analysis
  • Fig. 18 AI-Based Clinical Trials Solution Providers market: Therapeutic applications outlook and key takeaways
  • Fig. 19 Oncology market estimates and forecast, 2018 - 2030
  • Fig. 20 CVD market estimates and forecast, 2018 - 2030
  • Fig. 21 Neurological diseases or conditions market estimates and forecast, 2018 - 2030
  • Fig. 22 Metabolic diseases market estimates and forecast, 2018 - 2030
  • Fig. 23 Infectious diseases market estimates and forecast, 2018 - 2030
  • Fig. 24 Others market estimates and forecast, 2018 - 2030
  • Fig. 25 AI-Based Clinical Trials Solution Providers market: Clinical trial phase analysis
  • Fig. 26 AI-Based Clinical Trials Solution Providers market: Clinical trial phase outlook and key takeaways
  • Fig. 27 Phase-I market estimates and forecast, 2018 - 2030
  • Fig. 28 Phase-II market estimates and forecast, 2018 - 2030
  • Fig. 29 Phase-III market estimates and forecast, 2018 - 2030
  • Fig. 30 AI-Based Clinical Trials Solution Providers market: End use movement analysis
  • Fig. 31 AI-Based Clinical Trials Solution Providers market: End use outlook and key takeaways
  • Fig. 32 Pharmaceutical companies market estimates and forecast, 2018 - 2030
  • Fig. 33 Academia market estimates and forecast, 2018 - 2030
  • Fig. 34 Others market estimates and forecast, 2018 - 2030
  • Fig. 35 Global AI-based clinical trials solution providers market: Regional movement analysis
  • Fig. 36 Global AI-based clinical trials solution providers market: Regional outlook and key takeaways
  • Fig. 37 Global AI-based clinical trials solution providers market share and leading players
  • Fig. 38 North America market share and leading players
  • Fig. 39 Europe market share and leading players
  • Fig. 40 Asia Pacific market share and leading players
  • Fig. 41 Latin America market share and leading players
  • Fig. 42 Middle East & Africa market share and leading players
  • Fig. 43 North America: SWOT
  • Fig. 44 Europe SWOT
  • Fig. 45 Asia Pacific SWOT
  • Fig. 46 Latin America SWOT
  • Fig. 47 MEA SWOT
  • Fig. 48 North America market estimates and forecasts, 2018 - 2030
  • Fig. 49 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 50 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 51 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 52 UK market estimates and forecasts, 2018 - 2030
  • Fig. 53 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 54 France market estimates and forecasts, 2018 - 2030
  • Fig. 55 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 56 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 57 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 58 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 59 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 61 China market estimates and forecasts, 2018 - 2030
  • Fig. 62 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 63 India market estimates and forecasts, 2018 - 2030
  • Fig. 64 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 65 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 66 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 67 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 68 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 69 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 70 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 71 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 72 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 73 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 74 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 75 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 76 Company Categorization
  • Fig. 77 Company market position/share analysis
  • Fig. 78 Strategic Framework